A Study of PD-L1 Probody™ CX-072 in Adults with Solid Tumours
Research type
Research Study
Full title
A Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody™ Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
IRAS ID
269327
Contact name
Avinash Gupta
Contact email
Sponsor organisation
CytomX Theraputics, Inc
Eudract number
2019-000999-42
Duration of Study in the UK
2 years, 11 months, 3 days
Research summary
This is a Phase 2 study of a novel anti-cancer immune-modulating drug called CX-072, given in combination with other anticancer therapy, in adult patients with solid tumours. It is an open-label study, so both the patients and the doctors will know which drug the patient is taking. The study will have multiple groups of patients with solid tumours. These will include patients with unresectable cancer (ie: disease that cannot be removed with surgery), metastatic cancer (disease that has spread to other parts of the body), and patients with resectable disease where study treatment will be given as a first step to shrink the tumour before the main treatment of surgery.
In Part A of the study the main objective is to gather evidence of the effect of the study drug CX-072 in combination with ipilimumab, which is a licenced immunotherapy treatment for some types of cancer. This will be determined based on the response of the tumour to the drug as assessed by scans. The Response Evaluation Criteria in Solid Tumours will be used to evaluate this.
In Part B of the study the main objective is to obtain evidence of the anti-tumour effect of CX-072 in combination with ipilimumab in patients with certain solid tumours, based on the response of the disease to study treatment given as a first step to shrink the tumour prior to planned surgery.
REC name
North West - Greater Manchester South Research Ethics Committee
REC reference
19/NW/0696
Date of REC Opinion
21 Nov 2019
REC opinion
Favourable Opinion